BioCentury
ARTICLE | Clinical News

MT201: Started Phase I trial

November 5, 2001 8:00 AM UTC

Micromet GmbH, Munich, Germany Product: MT201 Business: Cancer Therapeutic category: Antibody, cytotoxic Target: Ep-CAM epithelial cell antigen Description: Human antibody against the Ep-CAM antigen...